TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Brief Summary: The purpose of this clinical research study is to examine the safety and effectiveness (how well the drug works) of two different treatments for patients with melanoma. One treatment is an investigational compound (a drug that is not currently approved by the United States Food and Drug Administration \[FDA\]), know as Ipilimumab (also known as MDX-010 or BMS-734016) together with an approved chemotherapy drug called Dacarbazine


Options:
A: Intervention Type: BIOLOGICAL; Name: GM2-KLH vaccine; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: QS21; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A
B: Arm Label: Arm A: Ipilimumab and Dacarbazine; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Drug: Dacarbazine | Arm Label: Arm B: Placebo and Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Dacarbazine | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Arm A: Ipilimumab and Dacarbazine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm B: Placebo and Dacarbazine | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Arm A: Ipilimumab and Dacarbazine, Arm B: Placebo and Dacarbazine
C: Arm Label: Sunitinib; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
D: Arm Label: Nivolumab, 3 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (Nivolumab), Drug: Placebo matching Dacarbazine | Arm Label: Dacarbazine, 1000 mg/m^2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Placebo matching BMS-936558 (Nivolumab), Drug: Dacarbazine | Intervention Type: BIOLOGICAL; Name: BMS-936558 (Nivolumab); Assigned to Arm(s): Nivolumab, 3 mg/kg | Intervention Type: BIOLOGICAL; Name: Placebo matching BMS-936558 (Nivolumab); Assigned to Arm(s): Dacarbazine, 1000 mg/m^2 | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine, 1000 mg/m^2 | Intervention Type: DRUG; Name: Placebo matching Dacarbazine; Assigned to Arm(s): Nivolumab, 3 mg/kg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Cross-Over Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing
Brief Summary: A randomized, cross-over, open-label study will be conducted to evaluate the equivalency, safety and tolerability of sevelamer once per day dosing, given with the largest meal, compared with standard three times per day dosing, in hemodialysis patients previously using sevelamer. Following a two week Run-In period, a total of 24 patients will be randomized to one of the following treatment sequences:

1. sevelamer dosed once a day with the largest meal followed by standard three times per day dosing with meals
2. sevelamer dosed three times per day with meals followed by once a day dosing with the largest meal. Patients will maintain a fixed daily dose throughout both treatment periods based on the most recently prescribed sevelamer dose prior to screening.


Options:
A: Arm Label: PA21 (2.5 g tablet); Type: EXPERIMENTAL; Interventions: Drug: PA21 (2.5 g tablet containing 500 mg iron) | Arm Label: Sevelamer carbonate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevelamer carbonate | Arm Label: PA21-1 (1.25 g tablet); Type: OTHER; Interventions: Drug: PA21-1 (1.25 g tablet containing 250 mg iron) | Intervention Type: DRUG; Name: PA21 (2.5 g tablet containing 500 mg iron); Assigned to Arm(s): PA21 (2.5 g tablet) | Intervention Type: DRUG; Name: Sevelamer carbonate; Assigned to Arm(s): Sevelamer carbonate | Intervention Type: DRUG; Name: PA21-1 (1.25 g tablet containing 250 mg iron); Assigned to Arm(s): PA21-1 (1.25 g tablet)
B: Intervention Type: DRUG; Name: Sevelamer hydrochloride; Assigned to Arm(s): N/A
C: Arm Label: Renal Function Group #1; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #2; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #3; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #4; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #5; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #6; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #7; Type: N/A; Interventions: N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Calcium Carbonate (Phosphate Binder); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: 1500 mg/d elemental calcium as calcium carbonate | Intervention Type: DIETARY_SUPPLEMENT; Name: 1500 mg/d elemental calcium as calcium carbonate; Assigned to Arm(s): Calcium Carbonate (Phosphate Binder) | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Open and Sequential Study to Evaluate the Efficacy and Safety of Bemiparin Administration on the Response to Treatment in Patients Diagnosed With Limited Small Cell Lung Cancer
Brief Summary: Main objective:

To evaluate whether the subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting on the first day of chemotherapy (CT), delays tumoral spread and increases progression-free survival.

Secondary objectives:

To evaluate whether the subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting with the onset of chemotherapy, increases global survival, improving the response rates to treatment with CT + RT (radiotherapy) and reduces the incidence of venous thromboembolism (VTE).


Options:
A: Arm Label: chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy at the investigator's discretion | Arm Label: dalteparin; Type: EXPERIMENTAL; Interventions: Drug: daltéparine, Drug: Chemotherapy at the investigator's discretion | Intervention Type: DRUG; Name: daltéparine; Assigned to Arm(s): dalteparin | Intervention Type: DRUG; Name: Chemotherapy at the investigator's discretion; Assigned to Arm(s): chemotherapy, dalteparin
B: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Placebo drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo drug | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo drug; Assigned to Arm(s): Placebo drug
C: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for semuloparin) | Intervention Type: DRUG; Name: Semuloparin sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Placebo (for semuloparin); Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bemiparin | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bemiparin; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Open and Sequential Study to Evaluate the Efficacy and Safety of Bemiparin Administration on the Response to Treatment in Patients Diagnosed With Limited Small Cell Lung Cancer
Brief Summary: Main objective:

To evaluate whether the subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting on the first day of chemotherapy (CT), delays tumoral spread and increases progression-free survival.

Secondary objectives:

To evaluate whether the subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting with the onset of chemotherapy, increases global survival, improving the response rates to treatment with CT + RT (radiotherapy) and reduces the incidence of venous thromboembolism (VTE).


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lenalidomide, Drug: Prednisone, Drug: Melphalan | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): A
B: Arm Label: saline solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline solution (placebo) | Arm Label: nadroparin calcium; Type: EXPERIMENTAL; Interventions: Drug: Nadroparin calcium | Intervention Type: DRUG; Name: Nadroparin calcium; Assigned to Arm(s): nadroparin calcium | Intervention Type: DRUG; Name: saline solution (placebo); Assigned to Arm(s): saline solution
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bemiparin | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bemiparin; Assigned to Arm(s): 1
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks | Intervention Type: DRUG; Name: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks; Assigned to Arm(s): A, B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Open and Sequential Study to Evaluate the Efficacy and Safety of Bemiparin Administration on the Response to Treatment in Patients Diagnosed With Limited Small Cell Lung Cancer
Brief Summary: Main objective:

To evaluate whether the subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting on the first day of chemotherapy (CT), delays tumoral spread and increases progression-free survival.

Secondary objectives:

To evaluate whether the subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting with the onset of chemotherapy, increases global survival, improving the response rates to treatment with CT + RT (radiotherapy) and reduces the incidence of venous thromboembolism (VTE).


Options:
A: Arm Label: saline solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline solution (placebo) | Arm Label: nadroparin calcium; Type: EXPERIMENTAL; Interventions: Drug: Nadroparin calcium | Intervention Type: DRUG; Name: Nadroparin calcium; Assigned to Arm(s): nadroparin calcium | Intervention Type: DRUG; Name: saline solution (placebo); Assigned to Arm(s): saline solution
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bemiparin | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bemiparin; Assigned to Arm(s): 1
C: Arm Label: A; Type: OTHER; Interventions: Drug: cisplatinum or carboplatin and e.g.etoposide. | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: cisplatinum or carboplatin and e.g.etoposide+enoxaparin | Intervention Type: DRUG; Name: cisplatinum or carboplatin and e.g.etoposide.; Assigned to Arm(s): A | Intervention Type: DRUG; Name: cisplatinum or carboplatin and e.g.etoposide+enoxaparin; Assigned to Arm(s): B
D: Intervention Type: DRUG; Name: dalteparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: diagnostic laboratory biomarker analysis; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Open and Sequential Study to Evaluate the Efficacy and Safety of Bemiparin Administration on the Response to Treatment in Patients Diagnosed With Limited Small Cell Lung Cancer
Brief Summary: Main objective:

To evaluate whether the subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting on the first day of chemotherapy (CT), delays tumoral spread and increases progression-free survival.

Secondary objectives:

To evaluate whether the subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting with the onset of chemotherapy, increases global survival, improving the response rates to treatment with CT + RT (radiotherapy) and reduces the incidence of venous thromboembolism (VTE).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bemiparin | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bemiparin; Assigned to Arm(s): 1
B: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for semuloparin) | Intervention Type: DRUG; Name: Semuloparin sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Placebo (for semuloparin); Assigned to Arm(s): Placebo
C: Arm Label: Certoparin; Type: EXPERIMENTAL; Interventions: Drug: Certoparin | Arm Label: Unfractionated Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated Heparin | Intervention Type: DRUG; Name: Certoparin; Assigned to Arm(s): Certoparin | Intervention Type: DRUG; Name: Unfractionated Heparin; Assigned to Arm(s): Unfractionated Heparin
D: Arm Label: High Risk for VTE recieving dalteparin; Type: EXPERIMENTAL; Interventions: Drug: dalteparin injection | Arm Label: High Risk for VTE No therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Risk for VTE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: dalteparin injection; Assigned to Arm(s): High Risk for VTE recieving dalteparin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Open and Sequential Study to Evaluate the Efficacy and Safety of Bemiparin Administration on the Response to Treatment in Patients Diagnosed With Limited Small Cell Lung Cancer
Brief Summary: Main objective:

To evaluate whether the subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting on the first day of chemotherapy (CT), delays tumoral spread and increases progression-free survival.

Secondary objectives:

To evaluate whether the subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting with the onset of chemotherapy, increases global survival, improving the response rates to treatment with CT + RT (radiotherapy) and reduces the incidence of venous thromboembolism (VTE).


Options:
A: Arm Label: saline solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline solution (placebo) | Arm Label: nadroparin calcium; Type: EXPERIMENTAL; Interventions: Drug: Nadroparin calcium | Intervention Type: DRUG; Name: Nadroparin calcium; Assigned to Arm(s): nadroparin calcium | Intervention Type: DRUG; Name: saline solution (placebo); Assigned to Arm(s): saline solution
B: Arm Label: Dabigatran; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran | Arm Label: Warfarin (INR of 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR of 2.0-3.0)
C: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin Sodium, Drug: Placebo | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin sodium, Drug: Placebo | Intervention Type: DRUG; Name: Semuloparin Sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Enoxaparin sodium; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Enoxaparin, Semuloparin
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bemiparin | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bemiparin; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Telepsychology-Service Delivery for Depressed Elderly Veterans
Brief Summary: The purpose of this study is to see whether therapy for elderly adults with major depression can be delivered effectively using videoconferencing technology ("telepsychology"), which allows a therapist and patient who are not in the same room as one another to communicate. We are interested in learning if this form of mental health service delivery is an acceptable alternative to traditional face-to-face therapy delivered with the therapist in the same room as the patient.


Options:
A: Arm Label: Behavioral Activation; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral activation psychotherapy | Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual care | Intervention Type: BEHAVIORAL; Name: Behavioral activation psychotherapy; Assigned to Arm(s): Behavioral Activation | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual Care
B: Arm Label: eMotion intervention; Type: EXPERIMENTAL; Interventions: Behavioral: eMotion | Arm Label: Waiting list control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: eMotion; Assigned to Arm(s): eMotion intervention
C: Arm Label: 4 face-to-face and smartphone-app; Type: EXPERIMENTAL; Interventions: Behavioral: 4 face-to-face therapy session and a smartphone-app | Arm Label: TAU; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CBT, treatment as usual | Intervention Type: BEHAVIORAL; Name: 4 face-to-face therapy session and a smartphone-app; Assigned to Arm(s): 4 face-to-face and smartphone-app | Intervention Type: BEHAVIORAL; Name: CBT, treatment as usual; Assigned to Arm(s): TAU
D: Arm Label: Telepsychology; Type: EXPERIMENTAL; Interventions: Behavioral: Telepsychology | Arm Label: Face-to-face therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Face-to-face therapy | Intervention Type: BEHAVIORAL; Name: Telepsychology; Assigned to Arm(s): Telepsychology | Intervention Type: BEHAVIORAL; Name: Face-to-face therapy; Assigned to Arm(s): Face-to-face therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Efficacy of Levosimendan in Patients With Acute Myocardial Infarction Complicated by Symptomatic Left Ventricular Failure.
Brief Summary: The purpose of this study is to determine the safety and efficacy of a 24 hour infusion with levosimendan in patients with acute myocardial infarction and heart failure after acute percutaneous coronary intervention (PCI) treatment.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: levosimendan | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, | Intervention Type: DRUG; Name: levosimendan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo,; Assigned to Arm(s): 2
B: Intervention Type: PROCEDURE; Name: angioplasty, transluminal, percutaneous coronary; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: coronary artery bypass; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: thrombolytic therapy; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: levosimendan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: dobutamine; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Tilarginine Acetate Injection intravenous infusion; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Brief Summary: Parkinson's disease (PD) is the second most common neurodegenerative disease in the US, affecting nearly 1 million Americans. Up to 82% of community dwelling individuals with PD complain of sleep disturbances, typically sleep fragmentation. Despite the high prevalence of sleep problems and their impact on the life of these individuals, there has been, until recently, little research focus on the problem. This will be a multi-site, double blind, placebo-controlled, two arm, parallel group, fixed-dose trial which will last 6 weeks. Seventy patients at four sites (30 at the PI's site and a total of 40 patients at three external sites) will be equally randomized to eszopiclone or placebo. The primary hypothesis is that eszopiclone will be superior to placebo for the treatment of insomnia in patients with Parkinson's disease


Options:
A: Arm Label: Eszopiclone; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Eszopiclone | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): Eszopiclone, Placebo
B: Arm Label: eszopiclone 3 mg; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone | Arm Label: zopiclone 7,5mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zopiclone | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): eszopiclone 3 mg | Intervention Type: DRUG; Name: Zopiclone; Assigned to Arm(s): zopiclone 7,5mg
C: Arm Label: eszopiclone; Type: EXPERIMENTAL; Interventions: Drug: eszopiclone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: eszopiclone; Assigned to Arm(s): eszopiclone | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: PSG; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lunesta, Drug: Placebo control | Intervention Type: DRUG; Name: Lunesta; Assigned to Arm(s): PSG | Intervention Type: DRUG; Name: Placebo control; Assigned to Arm(s): PSG

Answer: C